News
May 23
2011
Advion BioServices Opens Midwest Drug Discovery and Metabolism Center of Excellence
May 23
2011
May 2
2011
ARMGO Pharma Inc., Announces the Appointment of Dr. Sapan Shah as CEO
May 2
2011
TARRYTOWN, N.Y., May 2, 2011 /PRNewswire/ -- ARMGO Pharma Inc., has appointed Dr. Sapan Shah as Chief Executive Officer, effective immediately. Dr. Shah joins ARMGO from Shionogi Inc., where he served as President and Chief Executive Officer since 2002. In addition to his role as CEO, Dr. Shah will also join ARMGO Pharma's Board of Directors.
READ MORE about ARMGO Pharma Inc., Announces the Appointment of Dr. Sapan Shah as CEO
Mar 1
2011
Advion BioServices to Open New Laboratory in Indianapolis to Provide Metabolism, ADME Screening, and Other Early-Stage Bioanalytical Services to Life Sciences Customers, including Lilly
Mar 1
2011
Jan 31
2011
Allergan and MAP Pharmaceuticals Announce Collaboration on LEVADEX™ Investigational Therapy for Acute Migraine
Jan 31
2011
IRVINE, Calif. and MOUNTAIN VIEW, Calif., January 31, 2011 - Allergan, Inc. (NYSE: AGN) and MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced a collaboration within the United States for LEVADEX™, a self -administered, orally inhaled therapy that has completed Phase III clinical development for the treatment of acute migraine in adults. MAP Pharmaceuticals currently anticipates submitting its New Drug Application (NDA) for LEVADEX™ with the United States Food and Drug Administration (FDA) in the first half of 2011.
READ MORE about Allergan and MAP Pharmaceuticals Announce Collaboration on LEVADEX™ Investigational Therapy for Acute Migraine
Jan 6
2011
NextWave Pharmaceuticals Announces Launch of NEXICLON™ XR – First Extended-Release, Once-Daily Clonidine Oral Suspension and Tablet
Jan 6
2011
CUPERTINO, Calif. (January 6, 2011) –– NextWave Pharmaceuticals announced today the launch of NEXICLON™ XR (clonidine) for the treatment of hypertension.
NEXICLON XR provides for once-daily dosing, in suspension and tablet form, to be taken alone or concomitantly with other antihypertensive agents.
READ MORE about NextWave Pharmaceuticals Announces Launch of NEXICLON™ XR – First Extended-Release, Once-Daily Clonidine Oral Suspension and Tablet
Nov 5
2010
Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
Nov 5
2010
Sep 8
2010
Say Goodbye to Unwanted Love Handles: CoolSculpting by Zeltiq™ Receives FDA Clearance for Patented, Non-Invasive Cooling Treatment for Fat Reduction
Sep 8
2010
PLEASANTON, Calif. [Sept. 8, 2010] – Great news for men and women dealing with one of the most exercise and diet-resistant problem areas: “love handles.” CoolSculpting™ is now cleared by the U.S. Food and Drug Administration (FDA) for the non-invasive reduction of fat. ZELTIQ™, a global medical device company, developed the procedure which delivers a non-invasive, safe, and clinically proven method for the selective reduction of “love handles” or flank.
READ MORE about Say Goodbye to Unwanted Love Handles: CoolSculpting by Zeltiq™ Receives FDA Clearance for Patented, Non-Invasive Cooling Treatment for Fat Reduction
May 18
2010
LensAR Laser System™ Receives FDA Clearance for Use in Cataract Surgery
May 18
2010
Apr 22
2010
Aragon Pharmaceuticals Secures $22 Million in Series B Financing
Apr 22
2010
SAN DIEGO, April 22 /PRNewswire/ -- Aragon Pharmaceuticals Inc. today announced that it has secured $22 million in Series B financing.
New investor Aisling Capital participated in the financing along with existing investors OrbiMed Advisors and The Column Group. The financing brings the total dollar amount raised to $30 million since the company's formation in May 2009.
READ MORE about Aragon Pharmaceuticals Secures $22 Million in Series B Financing
Apr 8
2010
LensAR Strengthens Team with Appointments of Medical Monitor and Two Board Members
Apr 8
2010